Malo Teri L, Ali Karla N, Sutton Steven K, Perkins Rebecca B, Giuliano Anna R, Vadaparampil Susan T
a Lineberger Comprehensive Cancer Center, University of North Carolina , Chapel Hill , NC , USA.
b Department of Health Behavior , Gillings School of Global Pubic Health, University of North Carolina , Chapel Hill , NC , USA.
Hum Vaccin Immunother. 2016 Jun 2;12(6):1511-8. doi: 10.1080/21645515.2015.1132963. Epub 2016 Feb 2.
A physician's recommendation for human papillomavirus (HPV) vaccine is a key predictor of vaccine uptake; however, little is known about how physicians communicate about HPV vaccine with male patients. We sought to describe physicians' HPV vaccine communication practices with males who are of vaccine-eligible age (9-26 years). We surveyed representative samples of pediatric and family medicine physicians in Florida, and assessed whether physicians present HPV vaccine as optional or routine, and as a vaccine that prevents cancer. We also assessed the type of visit during which physicians discuss HPV vaccine with adolescent males and whether other healthcare providers in the practice discuss HPV vaccine or make the initial recommendation. We received 367 completed surveys (50.7% response rate). Few physicians (29.9%) reported they typically present HPV vaccine as routine to males ages 11-12 years, who constitute the target group for routine vaccination. When discussing HPV vaccination, many physicians reported somewhat or strongly emphasizing cancer prevention (80.0%). Physicians most often discussed HPV vaccine when they saw patients for well-child visits (93.0%) and least often at acute care visits (15.3%). Over half reported that at least one other healthcare professional in their practice discusses (56.1%) or makes the initial recommendation for (54.9%) HPV vaccination. Many physicians in our sample are presenting HPV vaccine as optional rather than routine and are missing opportunities to communicate with males about the vaccine. Our findings identify areas for future interventions to improve physicians' HPV vaccine communication and, ultimately, increase the use of this cancer-preventing vaccine.
医生对人乳头瘤病毒（HPV）疫苗的推荐是疫苗接种率的关键预测因素；然而，对于医生如何与男性患者交流HPV疫苗，我们却知之甚少。我们试图描述医生与符合疫苗接种年龄（9至26岁）男性之间关于HPV疫苗的交流情况。我们对佛罗里达州的儿科和家庭医学医生进行了代表性抽样调查，评估医生是将HPV疫苗作为可选项还是常规项来介绍，以及是否将其作为预防癌症的疫苗来介绍。我们还评估了医生与青春期男性讨论HPV疫苗时的就诊类型，以及诊所中的其他医疗服务提供者是否讨论HPV疫苗或做出初次推荐。我们共收到367份完整的调查问卷（回复率为50.7%）。很少有医生（29.9%）报告称，他们通常会将HPV疫苗作为常规疫苗向11至12岁的男性介绍，而这一年龄段的男性是常规疫苗接种的目标群体。在讨论HPV疫苗接种时，许多医生报告称，他们或多或少或强烈强调癌症预防（80.0%）。医生在进行儿童健康检查时最常讨论HPV疫苗（93.0%），而在急症护理就诊时讨论得最少（15.3%）。超过半数的医生报告称，诊所中至少有一名其他医疗专业人员会讨论HPV疫苗接种（56.1%）或做出HPV疫苗接种的初次推荐（54.9%）。我们样本中的许多医生将HPV疫苗作为可选项而非常规项来介绍，并且错失了与男性就该疫苗进行交流的机会。我们的研究结果确定了未来干预措施的方向，以改善医生对HPV疫苗的交流，最终增加这种癌症预防疫苗的使用。
